NMN dosage chart
This summary table compares available dose amounts and schedules by administration route.
| Route | Dose | Frequency & duration |
|---|---|---|
| Oral | 300 mg | Once daily · 60 days |
| Sublingual | 250 mg | Single administration · Single visit |
| Intravenous | 300 mg | Single infusion · Single visit |
| Transdermal | 5 mg labeled loading per patch | Single laboratory exposure · 18-hour release measurement |
NMN dosage by administration route
NMN oral dosage
A documented oral NMN regimen uses 300 mg once daily for 60 days. Other strengths and delivery forms require their own formulation-specific information.[1]
NMN is a precursor used in NAD+ synthesis. Oral supplementation may support NAD-related biomarker levels; those measurements do not establish a longevity benefit.[1][2][3]
NMN sublingual dosage
A measured sublingual exposure uses one 250 mg beta-NMN tablet held under the tongue for 3 minutes before swallowing the remaining saliva and tablet residue. This is a single-administration schedule; it does not establish a daily course or a treatment-cycle length.[4]
Sublingual NMN and swallowed NMN have different early metabolite profiles. The single-dose comparison did not show higher blood NMN or NAD+ levels with sublingual delivery.[4][1][2][3]
NMN intravenous dosage
A documented investigational IV amount is 300 mg in a single supervised infusion. Repeat-dose intervals and long-term infusion courses are not established.[5]
IV NMN is a distinct delivery context for an NAD+ precursor. Infusion formulation, delivery rate and monitoring require separate clinical information.[5][1][2][3]
NMN transdermal — ex vivo pva microneedle patch dosage
The PVA microneedle preparation has a labeled NMN loading of 5 mg per patch. Release is measured across excised porcine skin for 18 hours; the PVA-CMC formulation releases 91.94% during that experiment. The loading and laboratory observation period do not specify a human absorbed dose or patch-wearing schedule.[6]
PVA and carboxymethyl cellulose control release from the experimental array. The 18-hour measurement is a laboratory observation period, rather than directions to wear an NMN patch for 18 hours.[6][7][1][2][3]
NMN safety and side effects
Approval and product quality
NMN is not an FDA-approved drug.[10]
Side effects and long-term safety
Short-term oral NMN use has generally been tolerated without a consistent increase in serious adverse events. Multi-year use, pregnancy, pediatric use, cancer-specific risk, product quality and equivalence across formulations remain insufficiently studied.[11][12][9][1][2][8]
Common NMN dosage questions
Can NMN doses be transferred between routes?
What dosage is listed for NMN?
A documented oral NMN regimen uses 300 mg once daily for 60 days.[1]
